Yang, J;
Milasta, S;
Hu, D;
AlTahan, AM;
Interiano, RB;
Zhou, J;
Davidson, J;
... Davidoff, AM; + view all
(2017)
Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox.
Cancer Research
, 77
(17)
pp. 4626-4638.
10.1158/0008-5472.CAN-16-0826.
Preview |
Text
Nathwani_Targeting Histone Demethylases in MYC-Driven Neuroblastomas with Ciclopirox_AAM.pdf - Accepted Version Download (2MB) | Preview |
Abstract
Histone lysine demethylases facilitate the activity of oncogenic transcription factors, including possibly MYC. Here we show that multiple histone demethylases influence the viability and poor prognosis of neuroblastoma cells, where MYC is often overexpressed. We also identified the approved small-molecule antifungal agent ciclopirox as a novel pan-histone demethylase inhibitor. Ciclopirox targeted several histone demethylases, including KDM4B implicated in MYC function. Accordingly, ciclopirox inhibited Myc signaling in parallel with mitochondrial oxidative phosphorylation, resulting in suppression of neuroblastoma cell viability and inhibition of tumor growth associated with an induction of differentiation. Our findings provide new insights into epigenetic regulation of MYC function and suggest a novel pharmacologic basis to target histone demethylases as an indirect MYC-targeting approach for cancer therapy.
Archive Staff Only
 |
View Item |
